Compare Marathon Digital Holdings Inc (MARA) vs 10X Genomics Inc (TXG) Price & Performance

MARA stock trades at $10.36, down 5.56% today, with a bearish technical signal despite oscillators showing some bullish momentum. The company reported significant losses with a net income margin of -429.71% in 2026, though valuation ratios appear attractive with P/E of 3.37 and EV/EBITDA of 3.31. Recent earnings have consistently missed expectations, with Q2 2026 EPS of -1.60 versus expected 0.17.

The outlook remains challenging due to persistent losses and negative cash flow from operations. Analyst consensus is divided with 45% buy ratings and a $13.25 price target, suggesting 28% upside potential. Key risks include execution challenges, competitive pressures, and reliance on financing activities to sustain operations.

10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.

TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.